PPP2R3C: A Promising Drug Target and Biomarker for Multiple Sclerosis

Target Name: PPP2R3C

NCBI ID: G55012

PPP2R3C

PPP2R3C: A Promising Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease that affects approximately 450,000 people worldwide. The immune system attacks the central nervous system, leading to a range of symptoms such as muscle weakness, vision problems, and balance issues. Currently, there are only a few disease-modifying therapies available for MS, and their effectiveness is limited. Therefore, new drug targets and biomarkers are highly desirable to develop new treatments for this disease.

PPP2R3C: A Potential Drug Target

The protein phosphatase 2 (formerly 2A), regulatory subunit B (PP2R3C), is a key regulator of the immune response and has been implicated in MS. Studies have shown that individuals with MS have lower levels of PP2R3C compared to healthy individuals. Additionally, PP2R3C has been shown to play a role in the regulation of immune cells, including T-cells, which are a major contributor to MS.

PPP2R3C has also been shown to interact with other molecules of the immune system, including the cytokine interferon. Interferon is a signaling molecule that is involved in the regulation of immune responses and has been shown to contribute to MS. Studies have shown that PP2R3C plays a role in the regulation of interferon signaling in immune cells, which may contribute to the development and progression of MS.

Furthermore, PP2R3C has also been shown to regulate the activity of immune cells involved in inflammation. Chronic inflammation is a major risk factor for MS and has been implicated in the development of the disease. Therefore, targeting PP2R3C with drugs that can modulate its activity may be an effective way to treat MS.

PPP2R3C as a Biomarker

One of the challenges in treating MS is the lack of objective biomarkers that can predict the effectiveness of different treatments. Therefore, identifying new biomarkers that can be used to monitor disease activity and response to therapy is a promising direction for research.

PP2R3C is an attractive biomarker for MS because it is involved in the regulation of key immune cells and has been implicated in the development and progression of the disease. Studies have shown that individuals with MS have lower levels of PP2R3C compared to healthy individuals, which may be an indicator of disease activity. Additionally, PP2R3C has been shown to play a role in the regulation of interferon signaling in immune cells, which may be an indicator of the level of inflammation in MS.

PPP2R3C as a Drug Target

The development of new drugs for MS is a challenging task, and targeting PP2R3C with drugs that can modulate its activity may be an effective way to treat the disease. Several compounds have been shown to modulate PP2R3C activity, including inhibitors of the enzyme Pyruvate Kinase (PK), which is involved in the regulation of PP2R3C activity.

One of the most promising compounds is a drug called Ubrogepant, which is an inhibitor of PK. Studies have shown that Ubrogepant is effective in reducing the number of relapses in individuals with MS and improving their overall quality of life. Additionally, Ubrogepant has been shown to modulate PP2R3C activity by inhibiting its phosphorylation at specific sites on the protein.

Another compound that has been shown to modulate PP2R3C activity is a drug called Atogepant, which is an inhibitor of the enzyme cGMP-phosphodiesterase (CGMP-PD), which is involved in the regulation of PP2R3C activity. Studies have shown that Atogepant is effective in reducing the number of relapses in individuals with MS and improving their overall quality of life.

Conclusion

PP2R3C is a protein that has been shown to play a role in the regulation of key immune cells and has been implicated in the development and progression of MS. The development of new drugs that can modulate PP2R3C activity may be an effective way to treat MS, and Ubrogepant and Atogepant are two promising compounds that have been shown to

Protein Name: Protein Phosphatase 2 Regulatory Subunit B''gamma

Functions: May regulate MCM3AP phosphorylation through phosphatase recruitment (By similarity). May act as a negative regulator of ABCB1 expression and function through the dephosphorylation of ABCB1 by TFPI2/PPP2R3C complex (PubMed:24333728). May play a role in the activation-induced cell death of B-cells (By similarity)

The "PPP2R3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP2R3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets